- Conditions
- Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Systemic Amyloidosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- total-body irradiation, fludarabine phosphate, cyclosporine, mycophenolate mofetil, nonmyeloablative allogeneic hematopoietic stem cell transplantation, donor lymphocytes, peripheral blood stem cell transplantation, laboratory biomarker analysis
- Radiation · Drug · Procedure + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Seattle, Washington
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 560
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Esophageal Cancer, Neoplasms, Esophageal
- Interventions
- RAD001, XELOX, Carboplatin, Radiation
- Drug · Radiation
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Nashville, Tennessee
- Conditions
- Anemia
- Interventions
- Epoetin Alfa plus Iron
- Drug
- Lead sponsor
- University of Louisville
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Neuroblastoma
- Interventions
- filgrastim, sargramostim, carboplatin, cisplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, etoposide phosphate, ifosfamide, isotretinoin, melphalan, thiotepa, vincristine sulfate, conventional surgery, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 30 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Portland, Oregon + 4 more
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- Erlotinib hydrochloride
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 3
- States / cities
- San Diego, California • Durham, North Carolina • Memphis, Tennessee
- Conditions
- Non Small Cell Lung Cancer, Small Cell Lung Cancer, Thymoma, Thymus Neoplasms
- Interventions
- Esophageal sparing IMRT
- Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Breast Cancer
- Interventions
- filgrastim, anastrozole, carboplatin, cisplatin, cyclophosphamide, etoposide, thiotepa, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
- Interventions
- docetaxel, cisplatin, 5-FU, IMRT, cetuximab, carboplatin
- Drug · Radiation
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Carboplatin, Paclitaxel, Lapatinib, Cisplatin, Ipsilateral Radiation, Bilateral Radiation, Transoral Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Sarcoma
- Interventions
- doxorubicin hydrochloride, ifosfamide and mesna, hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Mark Dewhirst
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Esophageal Cancer
- Interventions
- Induction Therapy - Capecitabine, Induction Therapy - Oxaliplatin, Combination Therapy - Capecitabine, Combination Therapy - Oxaliplatin, Combination Therapy - Radiation, Evaluation for response and surgery
- Drug · Radiation · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Pigmentation, Oxidative Stress
- Interventions
- Sunscreen application #1, Sunscreen application #2
- Other
- Lead sponsor
- Kenvue Brands LLC
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Union, New Jersey
- Conditions
- Malignant Glioma, Glioblastoma, Gliosarcoma
- Interventions
- Bevacizumab, Temozolomide, Radiation Therapy (XRT), Topotecan
- Drug · Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Melanoma, Skin Cancer
- Interventions
- Aldesleukin (IL-2), Recombinant Interferon Alfa (IFN-A), Cisplatin, Dacarbazine, Vinblastine, Adjuvant Therapy
- Biological · Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 10 Years to 70 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Kidney Cancer Metastatic, Kidney Cancer, Kidney Cancer, Stage IV
- Interventions
- Nivolumab/Ipilimumab, SBRT
- Drug · Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Dallas, Texas
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 390
- States / cities
- Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 290 more
- Conditions
- Pancreatic Cancer
- Interventions
- Gemcitabine, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 228
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Fresno, California + 164 more
- Conditions
- Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, irinotecan hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 7
- States / cities
- Chapel Hill, North Carolina • Goldsboro, North Carolina • Greenville, North Carolina + 4 more
- Conditions
- Brain Tumors, Central Nervous System Tumors
- Interventions
- etoposide, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 73 more
- Conditions
- Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
- Interventions
- Biospecimen Collection, Brachytherapy, Carboplatin, Chest Radiography, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography
- Procedure · Radiation · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 344
- States / cities
- Birmingham, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 265 more
- Conditions
- Cancer of the Head and Neck, Radiotherapy
- Interventions
- Not listed
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Head and Neck Cancer
- Interventions
- ZD 1839 500mg
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
- Interventions
- Anti-PD-L1 Monoclonal Antibody MPDL3280A, Stereotactic Body Radiation Therapy
- Drug · Radiation
- Lead sponsor
- Megan Daly, MD
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Ventricular Tachycardia, Sudden Cardiac Death
- Interventions
- Functional Substrate-Only Mapping without VT Induction, Standard-of-Care Mapping/Imaging
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Diego, California